Related Experiment Video
Updated: Jul 6, 2026
12:44
The In ovo CAM-assay as a Xenograft Model for Sarcoma
Published on: July 17, 2013
The clinical approach towards chondrosarcoma.
Hans Gelderblom1, Pancras C W Hogendoorn, Sander D Dijkstra
1Department of Clinical Oncology (Medical Oncology and Radiotherapy), Leiden University Medical Center, PO Box 9600, Postzone K1-P, 2300RC Leiden, The Netherlands. a.j.gelderblom@lumc.nl
The Oncologist
|April 2, 2008
Summary
This review details skeletal chondrosarcoma diagnosis and treatment. It covers primary and secondary tumors, rare subtypes, and imaging techniques, emphasizing surgical resection for high-grade tumors and adjuvant therapies for low-grade variants.
Area of Science:
- Orthopedic Oncology
- Skeletal Pathology
- Cancer Histopathology
Background:
- Chondrosarcoma is a malignant cartilage tumor of bone.
- Primary chondrosarcomas arise de novo, while secondary types develop from benign cartilage neoplasms.
- Classification includes location (central, peripheral, juxtacortical) and histological grade, impacting prognosis.
Purpose of the Study:
- To provide a comprehensive overview of skeletal chondrosarcoma.
- To discuss histopathology, classification, diagnostic imaging, and therapeutic strategies.
- To highlight rare subtypes and emerging treatment targets.
Main Methods:
- Review of existing literature on chondrosarcoma.
- Analysis of histopathological features and grading systems.
- Evaluation of diagnostic modalities including MRI and CT scans.
- Assessment of surgical, radiotherapeutic, and chemotherapeutic treatment outcomes.
Main Results:
- Histological grading is crucial for prognosis but has interobserver variability.
- MRI and CT are essential for preoperative staging and surgical planning.
- Wide surgical excision is standard for intermediate- and high-grade chondrosarcoma.
- Curettage with adjuvant therapy shows promise for low-grade tumors.
- Radiotherapy requires high doses (>60 Gy) for incomplete resections; proton therapy may be beneficial.
- Chemotherapy is primarily effective in mesenchymal chondrosarcoma.
Conclusions:
- Skeletal chondrosarcoma management requires a multidisciplinary approach.
- Accurate diagnosis, staging, and appropriate treatment selection are critical for patient outcomes.
- Further research into novel systemic therapies is warranted for challenging subtypes.
